Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at S

StockNews.com assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the stock. CRVS has been the subject of several other research reports. Cantor Fitzgerald raised their price target on Corvus Pharmaceuticals from $2.00 to $4.00 in a […]

Related Keywords

, Institutional Trading Of Corvus Pharmaceuticals , News Ratings For Corvus Pharmaceuticals Daily , Discovery Capital Management , Corvus Pharmaceuticals , Corvus Pharmaceuticals Trading , Renaissance Technologies , Corvus Pharmaceuticals Inc , Cantor Fitzgerald , Nasdaq , Corvus Pharmaceuticals Company Profile , Get Rating , Capital Management , Sigma Advisers , Sigma Investments , Adenosine Production Inhibitor , Corvus Pharmaceuticals Daily , Nasdaq Crvs , Ccrvs , Medical , Initiated Coverage , Stocknews Com ,